Versantis, a Spin-off of ETH Zurich reinventing the diagnosis, prevention, and treatment of patients with liver diseases, announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to VS-01 for the treatment of patients with acute-on-chronic liver failure (ACLF).